Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 3.21M P/E - EPS this Y - Ern Qtrly Grth -
Income -5.91M Forward P/E -0.15 EPS next Y - 50D Avg Chg 12.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -81.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -97.00%
Recommedations 2.00 Quick Ratio 0.75 Shares Outstanding 3.20M 52W Low Chg 64.00%
Insider Own 0.03% ROA -88.01% Shares Float 63.77M Beta 0.33
Inst Own 2.41% ROE -391.64% Shares Shorted/Prior 204.48K/196.99K Price 0.68
Gross Margin - Profit Margin - Avg. Volume 570,343 Target Price 140.00
Oper. Margin - Earnings Date - Volume 1,838,184 Change 14.29%
About TC BioPharm (Holdings) plc

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

TC BioPharm (Holdings) plc News
04/04/24 TCBP Announces Execution of Non-Binding Letter of Intent for Acquisition of NK Platform Technologies
04/02/24 TCBP Increasing Treatment Capacity with Expanded Manufacturing Process
03/19/24 TCBP Adjourns General Meeting Until a Later Date
03/18/24 TCBP Announces Exercise of Series D Warrants For Cash
03/01/24 Bryan Kobel, CEO of TCBP, Appears on Nationally Syndicated "The Big Biz Show"
02/27/24 /C O R R E C T I O N -- TC BioPharm/
02/22/24 TCBP Announces MHRA Acceptance of Amendment for ACHIEVE UK Trial
02/15/24 TC BioPharm Management to Participate at Upcoming 7th CAR-TCR Summit Europe
02/14/24 TCBP Provides Shareholder Update and Highlights Upcoming Milestones
01/29/24 TC BioPharm Chief Executive Officer, Bryan Kobel Featured on 'The Big Biz Show'
01/18/24 TC BioPharm to Present at the Sequire Investor Summit
01/04/24 TC BioPharm Regains Compliance with Nasdaq Minimum Bid Price Requirement
01/03/24 TC BioPharm Announces Additional Cost Reduction Steps to Improve Financial Standing and Streamline Efficiencies
12/22/23 TC BioPharm Announces Closing of $3.5 Million Public Offering
12/19/23 TC BioPharm Announces Pricing of $3.5 Million Public Offering
12/18/23 TC BioPharm Announces Formation of Commercial Development Division, Led by Industry Veteran, Dr. Lauren Bor Ph.D
12/13/23 TC BioPharm Announces Plan to Implement ADS Ratio Change
11/28/23 TC BioPharm (TCBP) Falls Despite FDA Clearing IND for AML Drug
11/27/23 TC BioPharm Announces FDA Clearance of Phase 1B IND for TCB-008 in Acute Myeloid Leukemia
11/14/23 TC BioPharm Announces Successful Completion of Safety Cohort and Positive DSMB Results
TCBP Chatroom

User Image rjkalidas9 Posted - 51 minutes ago

$TCBP inhouse purchases heavy today, any news?

User Image j51lim Posted - 53 minutes ago

$TCBP

User Image History101 Posted - 3 hours ago

$TCBP only 6k shares traded after hours, but still up over 10%!! GLTALs!!

User Image RollingDollar Posted - 3 hours ago

$TCBP

User Image Goatrade Posted - 4 hours ago

$TCBP

User Image Goatrade Posted - 4 hours ago

$TCBP

User Image FadeMaster83 Posted - 5 hours ago

$TCBP

User Image Dollarking Posted - 6 hours ago

$TCBP

User Image Goatrade Posted - 12 hours ago

$TCBP

User Image BL3Terminal Posted - 13 hours ago

$TCBP a biotech leader in gamma-delta T cell therapies, is poised for significant growth with its recent intent to acquire NK platform technologies, enhancing cancer treatment options. This strategic move, aimed at operational efficiencies and market leadership, is crucial given the firm's financial strains. The company is exploring equity raises and strategic collaborations to manage fiscal pressures, making it a prime M&A target. Achievements in clinical trials and manufacturing enhancements further boost its acquisition appeal. TC BioPharm's commitment to high governance standards adds to its investment attractiveness, as it navigates financial and regulatory challenges to capitalize on its innovative therapies. This could potentially attract larger pharmaceutical firms seeking advanced cancer therapies, positioning TC BioPharm favorably in the market.

User Image j51lim Posted - 14 hours ago

$TCBP

User Image jasonthack Posted - 14 hours ago

$TCBP Getting higher guess it doesn’t matter must be naked shorting now

User Image BL3Terminal Posted - 16 hours ago

$TCBP TC BioPharm is at a pivotal moment, with upcoming strategic decisions critical to its future trajectory. The prospect of a buyout looms as a potentially advantageous outcome, offering a pathway to secure vital funding and continue its innovations in gamma-delta T cell therapies. As industry observers and stakeholders closely monitor, the unfolding developments will not only determine TC BioPharm’s operational path but could also redefine its position in the global biotech marketplace.

User Image BL3Terminal Posted - 16 hours ago

$TCBP Market Dynamics and Future Prospects Despite intense competition in the biotech industry, TC BioPharm’s specialization in gamma-delta T cell therapies provides it with a unique market niche. With the AML market expected to reach substantial growth, TC BioPharm’s strategic advancements position it to capitalize on these market dynamics, contingent upon overcoming its present financial and operational challenges.

User Image BL3Terminal Posted - 16 hours ago

$TCBP Operational Achievements and Competitive Edge TC BioPharm has marked significant milestones enhancing its appeal as an acquisition candidate: • Clinical Progress: The company has successfully completed the Safety Cohort and received positive evaluations from the Data Safety Monitoring Board for its ACHIEVE trial. • Manufacturing Advancements: Significant enhancements in manufacturing processes aim to substantially reduce costs and expand treatment capacities

User Image BL3Terminal Posted - 16 hours ago

$TCBP Financial and Regulatory Considerations: The success of this transaction hinges on finalizing a definitive agreement, securing adequate financing, and obtaining necessary regulatory approvals. Financial Strains and Survival Strategies Facing imminent financial exhaustion, TC BioPharm has actively explored various funding avenues: • Strategic Collaborations and Licensing: These alternatives could provide immediate financial relief and ongoing revenue-sharing opportunities without complete relinquishment of proprietary technologies. Speculations on M&A Prospects Amid financial turbulence, there is rampant speculation regarding potential mergers and acquisitions. These strategic decisions could provide TC BioPharm with critical financial support and enhanced operational capabilities, ensuring the sustainability of its innovative projects.

User Image BL3Terminal Posted - 16 hours ago

$TCBP Breakdown of Recent Strategic Initiatives: 3. Manufacturing Enhancement: Central to the acquisition strategy is the refinement of manufacturing processes, essential for scaling up production and reducing costs, thereby making therapies more affordable and accessible. 4. Market Positioning: The planned acquisition is viewed as a strategic expansion intended to potentially boost TC BioPharm’s future market valuation. By integrating complementary technologies, the company aims to optimize clinical trial processes and accelerate the commercial rollout of advanced therapies.

User Image BL3Terminal Posted - 16 hours ago

$TCBP Breakdown of Recent Strategic Initiatives: 1. Acquisition Goals: Integrating CAR-NK technologies is designed to enhance TC BioPharm’s therapeutic arsenal, potentially introducing new monotherapies and enhancing existing combination treatments with gamma-delta T cell therapies. This strategic integration is expected to elevate therapeutic outcomes, especially against solid tumors. 2. Strategic Synergies: Adopting CAR-NK technologies is anticipated to boost TC BioPharm’s clinical and manufacturing efficiencies, aligning with the company’s goal to strengthen its competitive stance in the cell therapy market by expanding treatment options and driving innovation.

User Image BL3Terminal Posted - 16 hours ago

$TCBP Situated at the crux of pioneering cancer therapy innovations and severe financial strain, TC BioPharm (Holdings) PLC epitomizes the high-stakes world of biotechnology. Specialized in allogeneic gamma-delta T cell therapies, the company is under pressure with funding projected to dry up by May 2024. This precarious financial situation has primed the company for critical strategic maneuvers that could greatly sway its future, potentially positioning it as an attractive acquisition target due to its innovative therapeutic approaches and urgent capital needs. Recently, TC BioPharm highlighted its aggressive strategic intentions by initiating a non-binding letter of intent (LOI) to acquire cutting-edge NK platform technologies. This move is aimed at enhancing its gamma-delta T cell therapy suite, specifically targeting CAR-NK technologies focused on CD-70 and HER2, which would synergize with TC BioPharm’s existing TCB-008 to increase efficacy against solid tumors.

User Image Oxinternet Posted - 1 day ago

$TCBP How’s my bestest buddy Ahmed doing? You still alive, fella?

User Image Stockfomo Posted - 1 day ago

$TCBP

User Image Coastalcool Posted - 1 day ago

@TangoToEvora No I am still very Bullish on $TCBP .

User Image Goatrade Posted - 1 day ago

$TCBP

User Image BL3Terminal Posted - 1 day ago

$TCBP Gap Filled.. Time to get back in

User Image Tekish11 Posted - 1 day ago

$TCBP no volume, but I’m going to scoop some more. This still might have juice.

User Image Blacky13 Posted - 1 day ago

$TCBP Anyone got Short sales data. Thanks in advance.

User Image VietxRichy Posted - 1 day ago

$TCBP added at 1.38

User Image j51lim Posted - 1 day ago

$TCBP

User Image Pepe2050 Posted - 1 day ago

$TCBP someone accumulated more than 200000 shares. Not selling any below 3$ minimum ...your target?

User Image j51lim Posted - 1 day ago

$TCBP

Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Randall Mark Edward 10% Owner 10% Owner Nov 30 Buy 5 70,000 350,000 382,963 01/11/23
Randall Kenneth Edward 10% Owner 10% Owner Nov 30 Buy 5 70,000 350,000 382,963 01/11/23
Renaissance Capital Partners L... 10% Owner 10% Owner Nov 30 Buy 5 70,000 350,000 136,834 01/11/23
Randall Kenneth Edward 10% Owner 10% Owner May 24 Buy 1.15 20,803 23,923 100,418 07/14/22